Rayner Pharmaceuticals limited have informed the MHRA that the batches listed in this notification do not include the concentration of phosphates in the product information.
Similar Posts
Medical devices: conformity assessment and the UKCA mark
How to conform with the legal requirements for placing medical devices on the market.
MHRA approves tisotumab vedotin for the treatment of cervical cancer
As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used
Medical devices: get regulatory advice from the MHRA
How to apply for a regulatory advice meeting on medical devices and in vitro diagnostic devices.
Clinical trials for medicines: apply for approval in the UK
How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Chris Kessler: How access to innovative rare therapies can transform the lives of children like Charlie
A story of hope, medical innovation, and the impact of effective regulation on access to treatment.
Form: Decentralised Manufacture: The designation step application form
Application Form to be completed by an Applicant and sent to the MHRA requesting consideration of an award of a Decentralised Manufacture (DM) Designation.